IDH1 and acute myeloid leukemia: In the Phase III AGILE trial (NCT03173248), Ivosidenib combined with azacitidine significantly improved overall survival compared to azacitidine alone (median overall Survival: 24.0 months vs. 7.9 months), establishing a new standard of care for IDH1-mutant AML [145, 146].